These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37229655)

  • 1. The 5-year risk of recurrence of grade 2/3 cervical intraepithelial neoplasia after treatment in a population screening programme by human papillomavirus status: A cohort study in central Italy.
    Visioli CB; Iossa A; Gorini G; Mantellini P; Lelli L; Auzzi N; Pierro CD; Carozzi FM; Zappa M
    J Med Screen; 2023 Dec; 30(4):191-200. PubMed ID: 37229655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incomplete excision of cervical intraepithelial neoplasia as a predictor of the risk of recurrent disease-a 16-year follow-up study.
    Alder S; Megyessi D; Sundström K; Östensson E; Mints M; Belkić K; Arbyn M; Andersson S
    Am J Obstet Gynecol; 2020 Feb; 222(2):172.e1-172.e12. PubMed ID: 31473226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.
    Schuurman TN; Schaafsma M; To KH; Verhoef VMJ; Sikorska K; Siebers AG; Wenzel HHB; Bleeker MCG; Roes EM; Zweemer RP; de Vos van Steenwijk PJ; Yigit R; Beltman JJ; Zusterzeel PLM; Lok CAR; Bekkers RLM; Mom CH; van Trommel NE
    Lancet Oncol; 2023 Dec; 24(12):1349-1358. PubMed ID: 37952541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
    Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
    PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
    Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
    Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
    Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
    Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
    Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
    BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
    Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
    BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus-vaccinated and unvaccinated women: a population-based cohort study.
    Krog L; Lycke KD; Kahlert J; Randrup TH; Jensen PT; Rositch AF; Hammer A
    Am J Obstet Gynecol; 2024 Apr; 230(4):430.e1-430.e11. PubMed ID: 38569830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
    El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
    Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result.
    Strang THR; Gottschlich A; Cook DA; Smith LW; Gondara L; Franco EL; van Niekerk DJ; Ogilvie GS; Krajden M
    Am J Obstet Gynecol; 2021 Nov; 225(5):511.e1-511.e7. PubMed ID: 34081897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
    Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
    BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
    Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
    BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.